Instructions for use Dekvadol lozenges with raspberry flavor No. 36
Composition
active ingredients:
1 tablet contains dequalinium chloride 0.25 mg, cinchocaine hydrochloride (dibucaine hydrochloride) 0.03 mg;
excipients:
mint-flavored tablets: sorbitol (E 420), talc, magnesium stearate, colloidal anhydrous silicon dioxide, mint oil, powdered food flavoring (mint);
lemon-flavored tablets: sorbitol (E 420), talc, magnesium stearate, colloidal anhydrous silicon dioxide, food flavoring "Lemon" (liquid);
raspberry-flavored tablets: sorbitol (E 420), talc, magnesium stearate, colloidal anhydrous silicon dioxide, food flavoring "Strawberry" (liquid), food flavoring powder (raspberry);
coconut-flavored tablets: sorbitol (E 420), talc, magnesium stearate, colloidal anhydrous silicon dioxide, food flavoring "Coconut" (liquid).
Dosage form
Tablets for resorption.
Main physicochemical properties:
mint-flavored tablets: white, flat-cylindrical tablets with a bevel and a score on one side, with a mint taste and smell;
Lemon-flavored tablets: white, flat-cylindrical tablets with a bevel and a score on one side, with a lemon taste and smell;
Raspberry-flavored tablets: white, flat-cylindrical tablets with a bevel and a score on one side, with a raspberry taste and smell;
Coconut-flavored tablets: white, flat-cylindrical tablets with a bevel and a score on one side, with the taste and smell of coconut.
Pharmacotherapeutic group
Drugs used in throat diseases. ATX code R02A.
Pharmacological properties
Pharmacodynamics
As a bactericidal and fungistatic agent, dequalinium chloride acts on microorganisms that cause mixed infections of the oral cavity and throat. The spectrum of action of this local chemotherapeutic agent is broad and includes most gram-positive and gram-negative bacteria, as well as fungi, spirochetes and pathogenic microorganisms that cause mixed infections of the oral cavity and throat. The accumulation of dibucaine hydrochloride in the body relieves the pain symptom that accompanies infections of the oral cavity and throat.
Microorganisms resistant to dequalinium chloride are unknown.
Does not cause caries.
Pharmacokinetics
The main active ingredient is absorbed in very small amounts.
Indication
Local treatment of acute inflammatory diseases of the oral cavity and throat: gingivitis, ulcerative and aphthous stomatitis, tonsillitis, laryngitis and pharyngitis. Decvadol is also recommended for use in the presence of unpleasant odor from the mouth.
Decvadol can be used in cases of mixed infection of the oral cavity and throat (on the recommendation of a doctor); as an auxiliary drug in the treatment of catarrhal angina, lacunar angina and Plaut-Vincent angina; in case of candidiasis of the oral cavity and pharynx.
Recommended for use in the postoperative period after tonsillectomy and tooth extraction.
Contraindication
Hypersensitivity to any of the ingredients of the medicinal product. Allergy to quaternary ammonium compounds (e.g. benzalkonium chloride).
Interaction with other medicinal products and other types of interactions
The antibacterial activity of dequalinium is reduced when used simultaneously with anionic surfactants, such as toothpaste. The use of the drug should not be combined with the intake of cholinesterase inhibitors.
Application features
Since the medicine does not contain sugar, it can be used in patients with diabetes.
The medicinal product contains sorbitol and should not be used in patients with rare hereditary diseases such as fructose intolerance. Use with caution in patients with low plasma cholinesterase levels.
Use during pregnancy or breastfeeding
Pregnancy
Controlled studies have not been conducted. The drug can be used during pregnancy after consulting a doctor if the therapeutic effect outweighs the possible risk to the fetus.
Breastfeeding period
Clinical studies on the penetration of active substances into breast milk have not been conducted. The drug is not recommended for use during breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
Studies on the effect of the drug on the ability to drive and use machines have not been conducted. However, the likelihood that the drug may have any negative effect in this regard is very small.
Method of administration and doses
Adults and children from 12 years old
Apply 1 tablet every 2 hours, after the symptoms of inflammation have subsided – 1 tablet every 4 hours.
For children from 4 years old
Apply 1 tablet every 3 hours, after the symptoms of inflammation have subsided - 1 tablet every 4 hours.
The tablets should be dissolved slowly, without chewing. The duration of treatment is determined by the doctor individually. The patient should consult a doctor if after 5 days of treatment with the drug the symptoms have not disappeared or have worsened.
Children.
The medicine in this dosage form is not prescribed to children under 4 years of age.
Overdose
There are no data on overdose.
Adverse reactions
Sometimes hypersensitivity reactions may occur after using the drug, such as rash, itching, burning sensation, irritation of the mucous membrane of the mouth and throat. In rare cases, namely in case of abuse, ulceration and necrosis may occur. In case of any unusual reactions, the drug should be discontinued and a doctor should be consulted regarding further therapy.
Expiration date
3 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
6 tablets in a blister; 3 or 5 blisters in a pack.
Vacation category
Without a prescription.
Producer
JSC "KYIV VITAMIN FACTORY".
Address
04073, Ukraine, Kyiv, Kopylivska St., 38.
